UCB has announced new week 16 results from the phase 3 BE BOLD trial showing that bimekizumab delivered superior joint ...
Millions of people living with arthritis may unknowingly be eating foods that increase inflammation, joint stiffness, and ...
Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it ...
Adding a dual GLP-1/GIP receptor agonist to the psoriasis drug ixekizumab (Taltz) significantly improved outcomes in adults ...
Adults with moderate to severe psoriasis and overweight or obesity were more likely to achieve complete skin clearance plus ...
As rheumatologists prepare for EULAR 2026, Clinical Trials Arena takes a look at the most promising drugs in late-stage development for PsA.
Osteoarthritis, far from being “simply wear and tear,” demands a multifaceted management strategy, according to a speaker at ...
Everyday Health on MSN
Psoriatic arthritis: What defines minimal disease activity?
This measure of how well controlled your psoriatic arthritis is can be used to guide treatment decisions.
A new study has found that biologic class and treatment sequencing influences psoriatic arthritis risk in patients with ...
Patients with active psoriatic arthritis who have an inadequate response to TNF inhibitors, mainly those with elevated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results